• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 19, 2018

View Archived Issues

Bench Press: BioWorld looks at translational medicine

A significant fraction of knockout genes are embryonic lethal – that is, knocking them out causes mouse embryos to die before birth. Research into the function of those genes has focused on the embryos themselves, but researchers from the British Babraham Institute have shown that the majority of embryonic lethal genes affect the placenta. Read More

Financings

Novelion Therapeutics Inc., of Vancouver, British Columbia, said subsidiary Aegerion Pharmaceuticals Inc. entered a secured financing facility with affiliates of Sarissa Capital Management and Broadfin Capital providing for a $20 million term loan to Aegerion, which has been fully drawn.  Read More

Lundbeck buying Prexton in back-loaded deal worth up to $1.1B; $123M up front

DUBLIN – H. Lundbeck A/S is acquiring Prexton Therapeutics Ltd. for €100 million up front (US$123 million) and up to €805 million more in development, regulatory and commercial milestones, in a deal that gives it ownership of foliglurax (PXT-002331), a first-in-class metabotropic glutamate receptor 4 (mGluR4) agonist currently undergoing a phase II trial as adjunct therapy in Parkinson's disease. Read More

Fosun, Ipsen join tech investor Arix's $121M capital raise

LONDON – Quoted technology investor Arix Bioscience plc closed its capital raise at £87 million (US$121 million) after investors took up 14.2 million of the 20 million shares available in the open offer announced on Feb. 28. Read More

As IBD drug Arena swarms, patient pool to include more cases tagged mild, moderate

Given the timing of the company's earnings call last week, investors might have expected phase II data with etrasimod in ulcerative colitis (UC) from Arena Pharmaceuticals Inc., but eagerly awaited results from the 157-patient phase experiment testing the oral sphingosine-1-phosphate (S1P) receptor modulator will not roll out until later this month. Read More

CSL Behring plants giant footprint in rare CIDP with Hizentra approval

On the heels of last year's FDA nod for Privigen (immune globulin intravenous, human, 10 percent liquid), CSL Behring, a unit of Australia's CSL Ltd., gained the agency's green light for Hizentra (immune globulin subcutaneous [human] 20 percent liquid) as the first subcutaneous immunoglobulin (SCIg) therapy to treat chronic inflammatory demyelinating polyneuropathy (CIDP). The drug, approved by the FDA in 2010 to treat primary immunodeficiency (PI), is indicated as maintenance therapy in adults with CIDP to prevent relapse of neuromuscular disability and impairment. Read More

Hong Kong PolyU collaborates with European institutions on R&D platform

HONG KONG – Hong Kong Polytechnic University (PolyU) is partnering with two European institutions to establish a life sciences and engineering R&D platform to spearhead applied research. Read More

Other news to note

Foundation Medicine Inc., of Cambridge, Mass., said Japan-based Chugai Pharmaceutical Co. Ltd. will broaden patient access to its genomic profiling (CGP) services for individuals with advanced cancer.  Read More

In the clinic

Tetra Discovery Partners Inc., of Grand Rapids, Mich., said the FDA accepted the IND for BPN-14770, a selective small-molecule inhibitor of the phosphodiesterase type-4D enzyme, which research suggests may be useful in the treatment of fragile X syndrome and possibly other autism spectrum disorders.  Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 24, 2025.
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • HHS Secretary Robert Kennedy

    HHS budget hearing mashup of the worst and the best

    BioWorld
    “I expressed deep concerns with your nomination, Secretary Kennedy, and somehow, unfortunately, you have exceeded my expectations in the worst possible ways,”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe